Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ELANE | P08246 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.81 |
| ▸ | PPARG | P37231 | 2/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Demethylnobiletin SCHEMBL31237479 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| 5-Demethylnobiletin SCHEMBL1764120 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL17963714 | 0.95 | ALDH1A1 (0.91) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL25263457 | 0.93 | ALDH1A1 (0.86) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL1764664 | 0.93 | ALDH1A1 (0.86) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL10997058 | 0.91 | ALDH1A1 (0.88) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL1764085 | 0.91 | ALDH1A1 (0.84) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL25383379 | 0.90 | ALDH1A1 (0.82) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| SCHEMBL25225757 | 0.90 | ALDH1A1 (0.82) | ALDH1A1MAPTCYP3A4MAPK1USP2 | |
| Nobiletin SCHEMBL22092292 | 0.90 | ALDH1A1 (1.00) | ALDH1A1MAPTCYP3A4MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | DEEPSENSE BIOTECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12590094-B2 | Compounds for the treatment of neurodegenerative and metabolic disorders | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-31 | — | — | US | disclosed |
| CN-115920074-B | Mesoporous silicon nano delivery carrier, medicine-carrying compound, preparation method and application | 黄冈师范学院 | 2023-08-25 | — | — | CN | disclosed |
| CN-115920074-B | Mesoporous silicon nano delivery carrier, medicine-carrying compound, preparation method and application | 黄冈师范学院 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023108169-A2 | METHODS AND COMPOSITIONS FOR THE BIOSYNTHESIS AND USE OF DEMETHYLATED POLYMETHOXY FLAVONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-115920074-A | Mesoporous silicon nano delivery carrier, drug-loaded compound, preparation method and application | 黄冈师范学院 | 2023-04-07 | — | — | CN | disclosed |
| CN-115920074-A | Mesoporous silicon nano delivery carrier, drug-loaded compound, preparation method and application | 黄冈师范学院 | 2023-04-07 | — | — | CN | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| CN-114432294-A | 5-demethylnobiletin and preparation method and application thereof | 天津商业大学 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590094-B2 | Compounds for the treatment of neurodegenerative and metabolic disorders | TXN2, SMN1; SMN2, SNCA | ALDH1A1 237/4885MAPT 33/4885CYP3A4 3176/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | ALDH1A1 495/4885MAPT 11/4885CYP3A4 4118/4885 |
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | PLIN3, PNLIP, FABP2 | ALDH1A1 2873/4885MAPT 4716/4885CYP3A4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.